Envista Holdings Corp (NVST) Shares Surge 3.1% -- What GF Score of 82 Tells Investors
On May 20, 2026, Envista Holdings Corp (NVST) shares rose 3.1% to a current price of $23.77. This move comes in the context of a 52-week range of $16.41 to $30.
NVST - Envista Holdings Corp
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$27.44
DETAILS
HIGH:
$35.00
LOW:
$19.00
MEDIAN:
$25.00
CONSENSUS:
$27.44
UPSIDE:
17.11%
Stock News
Why Envista (NVST) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Envista Q1 Earnings Call Highlights
Envista NYSE: NVST reported a strong start to 2026, with management citing broad-based growth across its major dental businesses, margin expansion and continued investment in new products and commercial capabilities.
Envista (NVST) International Revenue Performance Explored
Explore Envista's (NVST) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Envista (NVST) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista: Spotlight On Q1 Outperformance And New Growth Drivers
My existing 'buy' rating for Envista is left unchanged following my evaluation of its results and outlook. NVST's 1Q2026 earnings beat consensus by 15%, thanks to a defensive dental market and the company's own cost reduction efforts. The company's high-teens EPS growth guidance for the full year is well-supported by new product launches and synergies relating to its latest M&A.
Envista Holdings Corporation (NVST) Q1 2026 Earnings Call Transcript
Envista Holdings Corporation (NVST) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Envista (NVST) Q1 Earnings
The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Envista (NVST) Surpasses Q1 Earnings and Revenue Estimates
Envista (NVST) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.24 per share a year ago.
Envista Reports First Quarter 2026 Results
BREA, Calif., May 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.
Financial Survey: Stagezero Life Sciences (OTCMKTS:SZLSF) and Envista (NYSE:NVST)
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings This table compares Stagezero Life
Envista Holdings Corporation $NVST Shares Purchased by Cwm LLC
Cwm LLC boosted its stake in Envista Holdings Corporation (NYSE: NVST) by 55.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,217 shares of the company's stock after buying an additional 25,905 shares during the period. Cwm LLC's holdings
Envista Schedules First Quarter 2026 Earnings Call
BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026.
Here's Why Envista (NVST) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Envista Holdings Corporation's NVST strategic priorities position it for robust growth in the upcoming quarters. The company is positioned to benefit from favorable long-term dental industry trends.
Envista Stock Up 42.5% in a Year: What's Driving It?
Envista NVST shares have climbed 42.5% over the past year, showcasing impressive momentum. The stock has outpaced the industry's 22.5% decline and the S&P 500 composite's 16.6% gain.
NVST or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Reviewing Envista (NYSE:NVST) & Nephros (NASDAQ:NEPH)
Nephros (NASDAQ: NEPH - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Volatility and Risk Nephros has a beta of 1.42, indicating
Here's Why Envista (NVST) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Price Targets
Envista price target raised to $33 from $30 at Evercore ISI
$33.00
(was $25.52)
Elizabeth Anderson
·
Evercore ISI
Envista price target raised to $31 from $30 at Baird
$31.00
(was $27.06)
Jeff Johnson
·
Robert W. Baird
Envista price target lowered to $30 from $32 at Evercore ISI
$30.00
(was $26.66)
Evercore ISI
Envista price target raised to $30 from $27 at Baird
$30.00
(was $28.36)
Robert W. Baird
Envista price target raised to $19 from $18 at Morgan Stanley
$19.00
(was $28.09)
Morgan Stanley
Envista price target raised to $32 from $26 at Evercore ISI
$32.00
(was $28.43)
Elizabeth Anderson
·
Evercore ISI
Envista price target raised to $31 from $27 at Stifel
$31.00
(was $24.71)
Stifel Nicolaus
Envista price target raised to $25 from $21 at Piper Sandler
$25.00
(was $24.71)
Jason Bednar
·
Piper Sandler
Leerink upgrades Envista to Outperform on improved growth, execution
$35.00
(was $24.71)
Leerink Partners
Envista price target raised to $27 from $25 at Stifel
$27.00
(was $23.27)
Jonathan Block
·
Stifel Nicolaus
Envista price target raised to $25 from $22 at UBS
$25.00
(was $23.26)
Kevin Caliendo
·
UBS
Envista price target raised to $21 from $19 at Piper Sandler
$21.00
(was $23.39)
Piper Sandler
Envista upgraded to Neutral from Underperform at Mizuho
$24.00
(was $25.24)
Steven Valiquette
·
Mizuho Securities
Envista initiated with an Overweight at Barclays
$24.00
(was $20.01)
Barclays
Envista Holdings Corp. (NVST) PT Raised to $19 at Mizuho
$19.00
(was $20.35)
Steven Valiquette
·
Mizuho Securities
Envista price target raised to $27 from $25 at Baird
$27.00
(was $20.14)
Robert W. Baird
Stifel Reiterates Buy Rating on Envista Holdings Corp. (NVST)
$25.00
(was $20.37)
Jonathan Block
·
Stifel Nicolaus
Envista added to 'Tactical Outperform' list at Evercore ISI
$25.00
(was $20.40)
Evercore ISI
Envista upgraded to Outperform from Neutral at Baird
$23.00
(was $18.00)
Jeff Johnson
·
Robert W. Baird
Envista price target lowered to $18 from $21 at UBS
$18.00
(was $16.97)
Kevin Caliendo
·
UBS